Status:
COMPLETED
The Use of Faster Acting Aspart in Type 1 Diabetes Patients
Lead Sponsor:
University Hospital, Antwerp
Collaborating Sponsors:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Type 1 Diabetes
Insulin
Eligibility:
All Genders
16-100 years
Brief Summary
Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from tr...
Detailed Description
The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T\<70 and T\<54 mg/d...
Eligibility Criteria
Inclusion
- Type 1 diabetes patients
- Duration of diabetes \> 2 years
- Using CGM for \> 6 months
Exclusion
- Using SMBG
- Pregnancy
- Using glucocorticoids or immunosuppressive agents
- Active oncological problem
Key Trial Info
Start Date :
January 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
438 Patients enrolled
Trial Details
Trial ID
NCT04711382
Start Date
January 29 2018
End Date
January 1 2021
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antwerp University Hospital
Edegem, Antwerp, Belgium, 2650